44 - Current Treatment Approach for NTM lung Infection

Disclosure(s):

Charles L. Daley, MD: AN2 Therapeutics, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Bill & Melinda Gates Foundation: Advisor/Consultant (Ongoing); Bugworks Research, Inc.: Grant/Research Support (Terminated, June 30, 2024); Galapagos NV: Advisor/Consultant (Ongoing); Genentech: Advisor/Consultant (Ongoing); Hyfe: Advisor/Consultant (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Juvabis: Grant/Research Support (Ongoing); MannKind: Advisor/Consultant (Ongoing); Matinas Biopharma,: Advisor/Consultant (Ongoing); NobHill Therapeutics: Advisor/Consultant (Ongoing); Otsuka Pharmaceuticals: Advisor/Consultant (Terminated, July 31, 2024); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Spero Therapeutics,: Advisor/Consultant (Ongoing); Zambon: Advisor/Consultant (Ongoing)